Disease · HP_0000746
Delusion
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Delusion. Diseases, record HP_0000746. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0000746
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Delusion
- Open Targets ID
- HP_0000746
- Other names
- Delusions
- Highest stage of its drugs
- Phase 3, for 2 of its 5 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs5
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| RISPERIDONE | CHEMBL85 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| PIMAVANSERIN | CHEMBL2111101 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CITALOPRAM | CHEMBL549 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OLANZAPINE | CHEMBL715 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| QUETIAPINE | CHEMBL716 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets6
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| HTR2A | 5-hydroxytryptamine receptor 2A | 4 | Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2a (5-HT2a) receptor inverse agonist | Phase 3 | https://conductscience.org/library/genes/3356 | Drugs and targets |
| DRD2 | D(2) dopamine receptor | 3 | D2-like dopamine receptor antagonist; Dopamine D2 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/1813 | Drugs and targets |
| HTR2C | 5-hydroxytryptamine receptor 2C | 3 | Serotonin 2c (5-HT2c) receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3358 | Drugs and targets |
| DRD3 | D2-like dopamine receptor | 1 | D2-like dopamine receptor antagonist | Unknown | https://conductscience.org/library/genes/1814 | Drugs and targets |
| DRD4 | D2-like dopamine receptor | 1 | D2-like dopamine receptor antagonist | Unknown | https://conductscience.org/library/genes/1815 | Drugs and targets |
| SLC6A4 | Sodium-dependent serotonin transporter | 1 | Serotonin transporter inhibitor | Unknown | https://conductscience.org/library/genes/6532 | Drugs and targets |
Trials4
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03575052 | A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease | Phase 3 | 784 | 2024-12-31 | Neuropsychiatric Symptoms Related to Neurodegenerative Disease | PIMAVANSERIN | Its record names the disease | ClinicalTrials.gov |
| NCT00015548 | CATIE-Alzheimer's Disease Trial | Not applicable | 450 | Alzheimer's Disease | CITALOPRAM, OLANZAPINE, QUETIAPINE, RISPERIDONE | Its record names the disease | ClinicalTrials.gov | |
| NCT00249158 | A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia | Phase 3 | 344 | Dementia, Alzheimer Disease, Vascular Dementia | RISPERIDONE | Its record names the disease | ClinicalTrials.gov | |
| NCT00287742 | A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease | Phase 3 | 33 | Alzheimer's Disease, Dementia | RISPERIDONE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pimavanserin 34 mg vs Placebo: Treatment-emergent Adverse Events (TEAEs) | 119 of 392 | 115 of 392 | 784 | NCT03575052 | Trial comparisons |
| Pimavanserin 34 mg vs Placebo: deaths from any cause | 2 of 392 | 2 of 392 | 784 | NCT03575052 | Trial comparisons |
| Pimavanserin 34 mg vs Placebo: serious adverse events | 8 of 392 | 6 of 392 | 784 | NCT03575052 | Trial comparisons |
Papers from its trials11
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 17035647 | RESULT | 1 | PubMed |
| 12633121 | RESULT | 1 | PubMed |
| 38427485 | DERIVED | 1 | PubMed |
| 33176899 | DERIVED | 1 | PubMed |
| 32074412 | DERIVED | 1 | PubMed |
| 29045769 | DERIVED | 1 | PubMed |
| 28215900 | DERIVED | 1 | PubMed |
| 20214847 | DERIVED | 1 | PubMed |
| 19369318 | DERIVED | 1 | PubMed |
| 18519523 | DERIVED | 1 | PubMed |
1 to 10 of 11
See all 11 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0000746
GET https://conductscience.org/api/diseases/v1/HP_0000746/drugs